Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Primary Indications
Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS) aged 2 years and older.
## Adult Dosing
* **Initial dose:** 5 mg twice daily.
* **Titration:** Increase dose every 3 days as needed to a maximum of 20 mg twice daily. Doses may be adjusted based on clinical response and tolerability.
## Pediatric Dosing
* **Ages 2 to 10 years or weighing less than 30 kg:**
* **Initial dose:** 5 mg once daily.
* **Titration:** Increase dose every 3 days as needed to a maximum of 10 mg twice daily.
* **Ages over 10 years or weighing 30 kg or more:**
* **Initial dose:** 5 mg twice daily.
* **Titration:** Increase dose every 3 days as needed to a maximum of 20 mg twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosage adjustments are recommended, but patients may be more sensitive to the effects.
* **Renal Impairment:** Use with caution. No specific dosage adjustments are recommended.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic insufficiency.
* Acute narrow-angle glaucoma.
## Adverse Effects
**Common:** Somnolence, decreased appetite, aggression, ataxia, irritability, constipation, vomiting, fatigue, rash.
**Serious:** Serious skin reactions (e.g., Stevens-Johnson syndrome), respiratory depression, suicidal behavior and ideation, withdrawal symptoms upon discontinuation, dependence.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of profound sedation, respiratory depression, and death.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is metabolized by CYP2C19 and CYP3A4. Strong CYP2C19 inhibitors (e.g., fluconazole) can increase clobazam levels. Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin) may decrease clobazam levels.
* **Other Anticonvulsants:** Clobazam can affect levels of other antiepileptic drugs (AEDs); monitor AED levels and adjust doses as needed.
## Monitoring
* Monitor for somnolence and sedation, especially when initiating therapy or increasing the dose.
* Monitor for signs of withdrawal symptoms (e.g., anxiety, insomnia, seizures) if the drug is stopped abruptly.
* Monitor for behavioral changes, including suicidal ideation.
* Monitor for serious skin reactions.
* Monitor for respiratory depression, especially in patients with pre-existing respiratory conditions or those taking concomitant CNS depressants.
## Clinical Pearls
* Clobazam should be used as adjunctive therapy only for LGS seizures.
* Gradual tapering is recommended upon discontinuation to avoid withdrawal symptoms.
* Risk of dependence and abuse exists.
* Patients and caregivers should be advised about the risk of serious skin reactions and instructed to seek medical attention immediately if a rash develops.
* The onset of action can be gradual; clinical benefit may not be seen for several weeks.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for complete and up-to-date details.
